

ADDITIONAL FILE 1

Appendix 1: Search strategies

Appendix 2: Opioid conversion table

Appendix 3: Forest plot of 24-hour morphine consumption from all trials estimates

Appendix 4: TSA of 24-hour morphine consumption in the cholecystectomy subgroup, all trials

Appendix 5: TSA of 24-hour morphine consumption in the hysterectomy subgroup, all trials

Appendix 6: TSA of 24-hour morphine consumption in the mastectomy subgroup, all trials

Appendix 7: TSA of 24-hour morphine consumption in the orthopedic arthroplasty subgroup, all trials

Appendix 8: TSA of 24-hour morphine consumption in the spinal subgroup, all trials

Appendix 9: TSA of 24-hour morphine consumption in the thoracic surgery subgroup, all trials

Appendix 10: Forest plot of SAEs, all trials

Appendix 11: TSA of SAEs in the thoracic surgery subgroup, all trials

Appendix 12: Forest plot of VAS 6 hours at rest, all trials

Appendix 13: Forest plot of VAS 6 hours at mobilization, all trials

Appendix 14: Forest plot of VAS 24 hours at rest, all trials

Appendix 15: Forest plot of VAS 24 hours at mobilization, all trials

Appendix 16: Forest plot nausea, all trials

Appendix 17: Forest plot vomiting, all trials

Appendix 18: Forest plot sedation, all trials

Appendix 19: Forest plot dizziness, all trials

Appendix 1: Search strategies

Preliminary searches performed 13 November 2013

Total number of references identified: 16895 references

Number of duplicates removed: 3189 references

Number of references in final list: 13706 references

Batch name: 131113_J Wetterslev_GABA

Cochrane Central Register of Controlled Trials (CENTRAL)(Issue 10 of 12, 2013) in The Cochrane Library (2411 hits in CENTRAL)

#1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#4 (gaba* or neurontin* or neurotonin* or horizant*)

#5 #1 or #2 or #3 or #4

#6 MeSH descriptor: [Pain] explode all trees

#7 pain*

#8 #6 or #7

#9 #5 and #8

#10 adult* or middle age* or aged

#11 #9 and #10

MEDLINE (Ovid SP)(1946 to November 2013)(7072 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5. 1 or 2 or 3 or 4

6. exp Pain/

7. pain*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8. 6 or 7

9. 5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

EMBASE (1974 to November 2013)(3653 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

5. 1 or 2 or 3 or 4

6. exp pain/

7. pain*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
8. 6 or 7
9. 5 and 8
10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (<http://apps.webofknowledge.com>)(1900 to November 2013)(3759 hits)

- #3 3,759 #2 AND #1
- #2 385,187 TS=(pain*)
- #1 68,630 TS=(gaba* or neurontin* or neurotonin* or horizant*)

Preliminary searches performed 30 June 2014

Total number of references identified: 16861 references
Number of duplicates removed: 3592 references
Number of references in final list: 13569 references
Number of new references: 789 references

Batch name: 140701_J Wetterslev_GABA

Cochrane Central Register of Controlled Trials (CENTRAL)(Issue 6 of 12, 2014) in The Cochrane Library (2619 hits in CENTRAL)

- #1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #4 (gaba* or neurontin* or neurotonin* or horizant*)
- #5 #1 or #2 or #3 or #4
- #6 MeSH descriptor: [Pain] explode all trees
- #7 pain*
- #8 #6 or #7
- #9 #5 and #8
- #10 adult* or middle age* or aged
- #11 #9 and #10

MEDLINE (Ovid SP)(1946 to July 2014)(6319 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]
2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]
3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
5. 1 or 2 or 3 or 4
6. exp Pain/
7. pain*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
8. 6 or 7
9. 5 and 8
10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

EMBASE (1974 to July 2014)(3847 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]
2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]
3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
5. 1 or 2 or 3 or 4
6. exp pain/
7. pain*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
8. 6 or 7
9. 5 and 8
10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (<http://apps.webofknowledge.com>)(1900 to July 2014)(4076 hits)

#3 4,076 #2 AND #1

#2 417,945 TS=(pain*)

#1 72,059 TS=(gaba* or neurontin* or neurotonin* or horizant*)

Preliminary searches performed 14 November 2014

Total number of references identified: 17315 references

Number of duplicates removed: 4105 references

Number of references in final list: 13210 references

Number of new references: 462 references

Batch name: 141114_J Wetterslev_GABA NEW

Cochrane Central Register of Controlled Trials (CENTRAL)(Issue 11 of 12, 2014) (2645 hits)

#1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#4 (gaba* or neurontin* or neurotonin* or horizant*)

#5 #1 or #2 or #3 or #4

#6 MeSH descriptor: [Pain] explode all trees

#7 pain*

#8 #6 or #7

#9 #5 and #8

#10 adult* or middle age* or aged

#11 #9 and #10

MEDLINE (Ovid SP)(1946 to November 2014)(6549 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5. 1 or 2 or 3 or 4

6. exp Pain/

7. pain*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8. 6 or 7

9. 5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

EMBASE (1974 to November 2014)(3962 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

5. 1 or 2 or 3 or 4

6. exp pain/

7. pain*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

8. 6 or 7

9. 5 and 8

10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (1900 to November 2014)(4159 hits)

#3 4,159 #2 AND #1

#2 417,588 TS=(pain*)

#1 72,305 TS=(gaba* or neurontin* or neurotonin* or horizant*)

Preliminary searches performed 9 April 2015

Total number of references identified: 17466 references

Number of duplicates removed: 4042 references

Number of references in final list: 13424 references

Number of new references: 126 references

Batch name: 150409_J Wetterslev_GABA

Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3 of 12, 2015) (2629 hits)

#1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#4 (gaba* or neurontin* or neurotonin* or horizant*)

#5 #1 or #2 or #3 or #4

#6 MeSH descriptor: [Pain] explode all trees

#7 pain*

#8 #6 or #7

#9 #5 and #8

#10 adult* or middle age* or aged

#11 #9 and #10

MEDLINE (Ovid SP)(1946 to April 2015) (6432 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]
2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]
3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
5. 1 or 2 or 3 or 4
6. exp Pain/
7. pain*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
8. 6 or 7
9. 5 and 8
10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

EMBASE (1974 to April 2015) (4081 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]
2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]
3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
5. 1 or 2 or 3 or 4
6. exp pain/
7. pain*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
8. 6 or 7
9. 5 and 8
10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (1900 to April 2015) (4324 hits)

- #3 4,324 #2 AND #1
#2 430,421 TS=(pain*)
#1 73,791 TS=(gaba* or neurontin* or neurotonin* or horizant*)

Preliminary searches performed 23rd September 2015

Total number of references identified: 18200 references
Number of duplicates removed: 4184 references
Number of references in final list: 14016 references
Number of new references: 1188 references

Batch name: 150915_J Wetterslev_GABA

Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8 of 12, 2015) (2798 hits)

- #1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #4 (gaba* or neurontin* or neurotonin* or horizant*)
- #5 #1 or #2 or #3 or #4

- #6 MeSH descriptor: [Pain] explode all trees
- #7 pain*
- #8 #6 or #7
- #9 #5 and #8
- #10 adult* or middle age* or aged
- #11 #9 and #10

MEDLINE (Ovid SP) (1946 to September 2015) (6621 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]
2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]
3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
5. 1 or 2 or 3 or 4
6. exp Pain/
7. pain*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
8. 6 or 7
9. 5 and 8
10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

EMBASE (1974 to September 2015) (4289 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]
2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]
3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
5. 1 or 2 or 3 or 4
6. exp pain/
7. pain*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
8. 6 or 7
9. 5 and 8
10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (1900 to September 2015) (4492 hits)

- #3 4,492 #2 AND #1
- #2 445,898 TS=(pain*)
- #1 75,431 TS=(gaba* or neurontin* or neurotonin* or horizant*)

Preliminary searches performed 12th April 2016

Total number of references identified:	references
Number of duplicates removed:	references
Number of references in final list:	references
Number of new references:	references

Batch name: 160412_J Wetterslev_GABA

Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 4 of 12, 2015) (2993 hits)

- #1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]
- #4 (gaba* or neurontin* or neurotonin* or horizant*)
- #5 #1 or #2 or #3 or #4
- #6 MeSH descriptor: [Pain] explode all trees
- #7 pain*
- #8 #6 or #7
- #9 #5 and #8
- #10 adult* or middle age* or aged
- #11 #9 and #10

MEDLINE (Ovid SP) (1946 to April 2016) (6625 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]
2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]
3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
5. 1 or 2 or 3 or 4
6. exp Pain/
7. pain*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
8. 6 or 7
9. 5 and 8
10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

EMBASE (1974 to April 2016) (4474 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]
2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]
3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]
4. (gaba* or neurontin* or neurotonin* or horizant*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
5. 1 or 2 or 3 or 4
6. exp pain/
7. pain*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
8. 6 or 7
9. 5 and 8
10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (1900 to April 2016) (4717 hits)

- #3 #2 AND #1
- #2 TS=(pain*)
- #1 TS=(gaba* or neurontin* or neurotonin* or horizant*)

Google Scholar search

After the 1st search, 13th November 2013

Gabapentin AND Postoperative pain
Gabapentin AND Acute pain management
Gabapentin AND Perioperative pain management

After the 2nd search, 30th June 2014

Gabapentin AND Postoperative pain
Gabapentin AND Acute pain management
Gabapentin AND Perioperative pain management

Limits: titles from 1st November 2013 and on

After the 3rd search, 14th November 2014

Gabapentin AND Postoperative pain
Gabapentin AND Acute pain management
Gabapentin AND Perioperative pain management

Limits: titles from 1st June 2014 and on

After the 4th search, 9th April 2015

Gabapentin AND Postoperative pain
Gabapentin AND Acute pain management
Gabapentin AND Perioperative pain management

Limits: titles from 1st November 2014 and on

After the 5th search, 23rd September 2015

Gabapentin AND Postoperative pain
Gabapentin AND Acute pain management
Gabapentin AND Perioperative pain management

Limits: titles from 1st April 2015 and on

After the 6th search, 12th April 2016


Gabapentin AND Postoperative pain
Gabapentin AND Acute pain management
Gabapentin AND Perioperative pain management

Limits: titles from 1st September 2015 and on


Appendix 2: Opioid conversion table

Opioid	Administration	Opioid: Intravenous morphine
1 mg Fentanyl	i.v.	100 mg morphine
1 mg Hydromorphone	i.v.	5 mg morphine
1 mg Morphine oral	oral	0.33 mg morphine
1 mg Nalbuphine	i.v.	1 mg morphine
1 mg Pethidine/Meperidine	i.v.	0.13 mg morphine
1 mg Propoxyphene	i.v.	5 mg morphine
1 mg Tramadol oral	oral	0.07 mg morphine


Appendix 3: Forest plot of 24-hour morphine consumption from all trials estimates




Appendix 4: TSA of 24-hour morphine consumption in the cholecystectomy subgroup, all trials




Appendix 5: TSA of 24-hour morphine consumption in the hysterectomy subgroup, all trials




Appendix 6: TSA of 24-hour morphine consumption in the mastectomy subgroup, all trials




Appendix 7: TSA of 24-hour morphine consumption in the orthopedic arthroplasty subgroup, all trials




Appendix 8: TSA of 24-hour morphine consumption in the spinal subgroup, all trials




Appendix 9: TSA of 24-hour morphine consumption in the thoracic surgery subgroup, all trials




Appendix 10: Forest plot of SAEs from all trials




Appendix 11: TSA of SAEs in the thoracic surgery subgroup, all trials




Appendix 12: Forest plot of VAS 6 hours at rest, all trials




Appendix 13: Forest plot of VAS 6 hours at mobilization, all trials




Appendix 14: Forest plot of VAS 24 hours at rest, all trials




Appendix 15: Forest plot of VAS 24 hours at mobilization, all trials




Appendix 16: Forest plot nausea, all trials



Appendix 17: Forest plot vomiting, all trials



Appendix 18: Forest plot sedation, all trials



Appendix 19: Forest plot dizziness, all trials

